English to Russian Medical Medical: Pharmaceuticals

Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche‑sponsored Parent study who continue to receive ocrelizumab or are in safety follow-up at the time of the closure of their respective Parent study (WA21092, WA21093 or WA25046) are eligible for enrollment in this extension study.
Table 1 Schedule of Activities for Participants Continuing on Ocrelizumab Treatment
Table 2 Schedule of Activities for Participants Entering the Study in Safety Follow-Up